menu

Medical Program: Real-World Pattern of Biologic Use in Patients with Inflammatory Bowel Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Real-World Pattern of Biologic Use in Patients with Inflammatory Bowel Disease

close
Real-World Pattern of Biologic Use in Patients with Inflammatory Bowel Disease
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • In Collaboration with

  • Overview

    Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

    Chao Chen, PhD,Abraham G Hartzema, PhD,Hong Xiao, PhD,Yu-Jung Wei, PhD,Naueen Chaudhry, MD,Ofor Ewelukwa, MD,Sarah C Glover, DO,Ellen M Zimmermann, MD

    BACKGROUND AND AIMS:
    Medication persistence, defined as the time from drug initiation to discontinuation of therapy, has been suggested as a proxy for real-world therapeutic benefit and safety. This study seeks to compare the persistence of biologic drugs among patients with inflammatory bowel disease (IBD).

    METHODS:
    Patients with newly diagnosed IBD were included in a retrospective study using Truven MarketScan database. Treatment persistence and switching was compared among biologic medications including infliximab, adalimumab, certolizumab, golimumab, and vedolizumab. Predictors for discontinuation and switching were evaluated using time-dependent proportional hazard regression.

    RESULTS:
    In total, 5612 patients with Crohn's disease (CD) and 3533 patients with ulcerative colitis (UC) were included in this analysis. Less than half of the patients continued using their initial biologic treatment after 1 year (48.48% in CD cohort; 44.78% in UC cohort). In the first year, adalimumab had the highest persistence and lowest switching rates for both CD (median survival time: 1.04 years) and UC (median survival time: 0.84 years). In subsequent years, infliximab users were more likely to persist in the use of biologic. Combination therapy with immunomodulators significantly decreased the risk of discontinuation, especially when immunomodulator therapy was started more than 30 days before the biologic (hazard ratio [HR], 0.22; CI, 0.16, 0.32). The major predictors for noncompliance included infection and hospitalization.

    CONCLUSION:
    Overall, the persistence profiles of biologics suggest a high rate of dissatisfaction or adverse disease outcomes resulting in discontinuation and switching to a different agent. Early initiation of immunomodulators will substantially increase the persistence of biologic treatment.

  • Publish Date

    Release Date: 03/18/2020

Facebook Comments

Recommended
Details
Presenters
Comments
  • In Collaboration with

  • Overview

    Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

    Chao Chen, PhD,Abraham G Hartzema, PhD,Hong Xiao, PhD,Yu-Jung Wei, PhD,Naueen Chaudhry, MD,Ofor Ewelukwa, MD,Sarah C Glover, DO,Ellen M Zimmermann, MD

    BACKGROUND AND AIMS:
    Medication persistence, defined as the time from drug initiation to discontinuation of therapy, has been suggested as a proxy for real-world therapeutic benefit and safety. This study seeks to compare the persistence of biologic drugs among patients with inflammatory bowel disease (IBD).

    METHODS:
    Patients with newly diagnosed IBD were included in a retrospective study using Truven MarketScan database. Treatment persistence and switching was compared among biologic medications including infliximab, adalimumab, certolizumab, golimumab, and vedolizumab. Predictors for discontinuation and switching were evaluated using time-dependent proportional hazard regression.

    RESULTS:
    In total, 5612 patients with Crohn's disease (CD) and 3533 patients with ulcerative colitis (UC) were included in this analysis. Less than half of the patients continued using their initial biologic treatment after 1 year (48.48% in CD cohort; 44.78% in UC cohort). In the first year, adalimumab had the highest persistence and lowest switching rates for both CD (median survival time: 1.04 years) and UC (median survival time: 0.84 years). In subsequent years, infliximab users were more likely to persist in the use of biologic. Combination therapy with immunomodulators significantly decreased the risk of discontinuation, especially when immunomodulator therapy was started more than 30 days before the biologic (hazard ratio [HR], 0.22; CI, 0.16, 0.32). The major predictors for noncompliance included infection and hospitalization.

    CONCLUSION:
    Overall, the persistence profiles of biologics suggest a high rate of dissatisfaction or adverse disease outcomes resulting in discontinuation and switching to a different agent. Early initiation of immunomodulators will substantially increase the persistence of biologic treatment.

  • Publish Date

    Release Date: 03/18/2020

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/24/20